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Ketogenesis prevents diet-induced fatty liver injury
and hyperglycemia
David G. Cotter,1,2 Baris Ercal,1 Xiaojing Huang,1,3 Jamison M. Leid,1 D. André d’Avignon,3 Mark J. Graham,4 Dennis J. Dietzen,2
Elizabeth M. Brunt,5 Gary J. Patti,3,6 and Peter A. Crawford1,6,7
Department of Medicine, Center for Cardiovascular Research, 2Department of Pediatrics, and 3Department of Chemistry, Washington University, St. Louis, Missouri, USA. 4Isis Pharmaceuticals Inc., Carlsbad,

1

California, USA. 5Department of Pathology and Immunology and 6Department of Genetics, Washington University, St. Louis, Missouri, USA. 7Sanford-Burnham Medical Research Institute, Orlando, Florida, USA.

Nonalcoholic fatty liver disease (NAFLD) spectrum disorders affect approximately 1 billion individuals worldwide. However,
the drivers of progressive steatohepatitis remain incompletely defined. Ketogenesis can dispose of much of the fat that
enters the liver, and dysfunction in this pathway could promote the development of NAFLD. Here, we evaluated mice
lacking mitochondrial 3-hydroxymethylglutaryl CoA synthase (HMGCS2) to determine the role of ketogenesis in preventing
diet-induced steatohepatitis. Antisense oligonucleotide–induced loss of HMGCS2 in chow-fed adult mice caused mild
hyperglycemia, increased hepatic gluconeogenesis from pyruvate, and augmented production of hundreds of hepatic
metabolites, a suite of which indicated activation of the de novo lipogenesis pathway. High-fat diet feeding of mice with
insufficient ketogenesis resulted in extensive hepatocyte injury and inflammation, decreased glycemia, deranged hepatic TCA
cycle intermediate concentrations, and impaired hepatic gluconeogenesis due to sequestration of free coenzyme A (CoASH).
Supplementation of the CoASH precursors pantothenic acid and cysteine normalized TCA intermediates and gluconeogenesis
in the livers of ketogenesis-insufficient animals. Together, these findings indicate that ketogenesis is a critical regulator
of hepatic acyl-CoA metabolism, glucose metabolism, and TCA cycle function in the absorptive state and suggest that
ketogenesis may modulate fatty liver disease.

Introduction

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) are now the most common causes of liver
disease in Western countries (1). NAFLD-induced liver failure is
one of the most common reasons for liver transplantation. NAFLD
increases the risk of developing type 2 diabetes, worsens glycemic
control, and contributes to the pathogenesis of cardiovascular
disease and chronic kidney disease (2–4). The pathogenic mechanisms of NAFLD and NASH are incompletely understood but
are thought to involve abnormalities of hepatocyte metabolism,
hepatocyte autophagy and endoplasmic reticulum stress, hepatic
immune cell function, adipose tissue inflammation, and systemic
inflammatory mediators (2, 4–6). Perturbations of carbohydrate,
lipid, and amino acid metabolism occur in and contribute to obesity, diabetes, and NAFLD in humans and in model organisms
(reviewed in refs. 7–11). While hepatocyte abnormalities in cytoplasmic lipid metabolism are commonly observed in NAFLD (12),
the role of mitochondrial metabolism, which governs the oxidative and terminal “disposal” of fats, in NAFLD pathogenesis is less
clear. Nonetheless, most investigators agree that abnormalities
of mitochondrial metabolism occur in and contribute to NAFLD
(reviewed in refs. 13–15).
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Ketogenesis can dispose of as much as two-thirds of the fat
entering the liver (16). Thus, dysregulation of ketone body metabolism could potentially contribute to NAFLD pathogenesis. Hepatic
ketogenesis is activated in states of high fatty acid and diminished
carbohydrate availability and/or when circulating insulin concentrations are very low (17–20). Within hepatic mitochondria, ketogenic reactions condense β-oxidation–derived acetyl-CoA into the
ketone bodies acetoacetate (AcAc) and β hydroxybutyrate (βOHB).
In doing so, ketogenesis disposes of acetyl-CoA generated in
excess of the liver’s own energy needs and simultaneously recycles
2 moles of free coenzyme A (CoASH) per mole of ketone produced
(reviewed in refs. 17, 19, 20). Robust ketogenesis is limited to hepatocytes due to relatively restricted expression of the fate-committing ketogenic enzyme mitochondrial 3-hydroxymethylglutaryl-
CoA synthase (HMGCS2) under normal conditions (21). In
contrast, oxidative disposal of ketone bodies is nearly ubiquitous,
as all cells except hepatocytes express the fate-committing enzyme
of ketone body oxidation succinyl-CoA:3-oxoacid CoA transferase (SCOT) (22, 23). Within the mitochondria of extrahepatic tissues, βOHB is oxidized to AcAc, which is then directed toward the
TCA cycle for terminal oxidation via a reaction uniquely catalyzed
by SCOT (17). Despite its high capacity as a disposal pathway for
hepatic fatty acids, ketone body metabolism has been overlooked
as a potential therapeutic target in NAFLD.
Through incompletely defined mechanisms, obesity-associated hyperinsulinemia suppresses ketogenesis, creating a state
of relative ketogenic insufficiency and leading to hypoketonemia
in obese animal models and humans when compared with lean
jci.org   Volume 124   Number 12   December 2014
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Figure 1. Ketogenic insufficiency in mice treated with HMGCS2 ASO. (A) Immunoblot for HMGCS2 and actin using protein lysates derived from livers
of neonatal mice treated with either a scrambled sequence control ASO or HMGCS2 ASO. Mice were treated with ASO daily for 11 days, beginning on the
second day of life, and tissues and serum were collected on P12. Normalized protein abundance is quantified below. (B) Serum total ketone body (TKB)
concentrations (mM) and (C) hepatic TAG concentrations (mg/g tissue) on P12 in ASO-treated mice n = 4–6/group. (D) Immunoblot for HMGCS2 and actin
using protein lysates derived from the livers of adult mice treated with control or HMGCS2 ASO biweekly for 4 weeks beginning at 6 weeks of age. (E)
Serum TKB concentrations (mM) during fasting in adult mice treated with ASOs for 4 weeks. n = 3–5/group. *P < 0.05, ***P < 0.001 by Student’s t test
versus HMGCS2 ASO–treated mice, or as indicated.

controls (24–29). To test the hypothesis that impaired ketogenesis, even in carbohydrate-replete and thus “nonketogenic” states,
contributes to abnormal glucose metabolism and provokes steatohepatitis, we generated a mouse model of marked ketogenic
insufficiency and used complementary systems physiological
approaches and 13C-labeling–based high-resolution measures of
metabolic dynamics to characterize the wide-ranging effects of
ketogenic impairment.

Results

Ketogenic insufficiency causes abnormal hepatic glucose and lipid
metabolism. The ability of ketogenesis to influence hepatic glucose
and lipid homeostasis has only been preliminarily characterized.
To determine the consequences of impaired ketogenesis during
the highly ketogenic neonatal period, suckling mice were injected
s.c. (25 mg/kg) with an Hmgcs2-targeted antisense oligonucleotide (ASO) daily, beginning on the second day of extrauterine life.
Compared with littermates injected with scrambled sequence
control ASO, we found that HMGCS2 ASO treatment decreased
hepatic HMGCS2 protein abundance by 70% by postnatal day
12 (P12) (Figure 1A). These mice exhibited normal body weights
and blood glucose concentrations and displayed mildly decreased
plasma ketone body concentrations (0.9 ± 0.05 mM vs. 1.3 ± 0.17
mM in controls, n = 4–6/group, P < 0.05; Figure 1B and Supplemental Figure 1, A and B; supplemental material available online
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with this article; doi:10.1172/JCI76388DS1). Intriguingly, this partial loss of ketogenesis was associated with a nearly 7-fold increase
in hepatic triacylglycerol (TAG) concentrations (6.6 ± 1.2 mg/g
vs. 0.96 ± 0.2 mg/g tissue in controls, n = 4–6/group, P < 0.001;
Figure 1C). To determine whether HMGCS2-mediated ketogenesis plays a role in a model of adult NAFLD, we administered i.p.
injections of HMGCS2 ASO (25 mg/kg biweekly for 4 weeks) into
C57BL/6 male mice maintained on a standard low-fat chow diet.
After 4 weeks, we found that hepatic Hmgcs2 transcript abundance
was decreased by 88% compared with that in mice treated with
control ASO (n = 8–10 per group, P < 0.001), without diminishing the scant Hmgcs2 transcript abundance normally observed
in s.c. adipose tissue (ref. 30 and Supplemental Figure 1, C and
D). Immunoreactive HMGCS2 was eliminated from the liver in
HMGCS2 ASO–treated mice (Figure 1D). ASO treatment did not
diminish the protein abundance of cytoplasmic 3-hydroxymethylglutaryl-CoA synthase (HMGCS1), which catalyzes the penultimate reaction in mevalonate synthesis (Supplemental Figure 1E).
HMGCS2 ASO–treated mice exhibited markedly blunted
ketonemia in both baseline (fed) and nutrient-deprived states (Figure 1E). To confirm the inability of HMGCS2 ASO–treated mice
to effectively incorporate fatty acid–derived carbon into ketone
bodies, livers from control and HMGCS2 ASO–treated mice were
perfused ex vivo via the portal vein with an oxygenated buffer
containing the fatty acid [13C]octanoic acid. Quantitative mapping
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Figure 2. Hepatic injury in HFD-fed ketogenesis-insufficient mice. (A) Hepatic TAG concentrations (mg/g tissue) and (B) serum ALT activity (U/l) in
ASO-treated mice fed a standard low-fat chow diet (Chow) for 4 weeks or an HFD for 8 weeks; n = 4–5/group. (C) Representative H&E-stained sections of
liver from ASO-treated mice fed the indicated diet. Arrowheads indicate dying hepatocytes (acidophil bodies). Scale bars: 50 μm and 100 μm (bottom left
panel). (D) Representative ×20 fields showing immunostaining for F4/80+ and (E) SMA+ cells in cryosections of liver from ASO-treated mice fed an HFD for
8 weeks. Quantification for each is shown on the right. n = 5 random ×20 fields/liver and 19 random ×10 fields/liver, respectively (n = 3 animals/group).
**P < 0.01, ***P < 0.001 by Student’s t test or 2-way ANOVA.

of the 13C-label using 13C-edited proton NMR profiling (31–34)
revealed markedly blunted incorporation of the label into βOHB in
HMGCS2 ASO–treated mice in both the fed and overnight-fasted
states. These results confirm that HMGCS2 is required for effective derivation of ketone bodies from fatty acids and indicate that

livers of these mice exhibit impaired ketogenesis, i.e., are ketogenesis insufficient (Supplemental Figure 1F). Despite exhibiting
marked ketogenic impairment, we observed that HMGCS2 ASO–
treated mice fed a standard low-fat chow diet did not differ in body
weight, body composition, or food intake compared with control
jci.org   Volume 124   Number 12   December 2014
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Figure 3. Diminished glycemia and hepatic gluconeogenesis in HFD-fed ketogenesis-insufficient mice. (A) Blood glucose (mg/dl) and (B) percentage of
basal blood glucose in ASO-treated mice beginning at the onset of 60% HFD feeding. n = 8–10/group. (C) Body weight and (D) caloric intake (kcal/mouse/
day) during 60% HFD maintenance and ASO treatment. n = 8–10/group. ***P < 0.001 by linear regression t test. (E) Quantification of fractional 13C enrichment of glucose from [13C]pyruvate (a surrogate for gluconeogenesis) determined by 13C-edited proton NMR spectroscopy in liver extracts of 60% HFD-fed
ASO-treated mice perfused via the portal vein with [13C]lactate and [13C]pyruvate in a physiological ratio. n =4–5/group. (F) Total hepatic glucose concentration (pmol/mg tissue) and (G) moles of 13C-glucose produced from [13C]lactate and [13C]pyruvate, quantified by NMR profiling of perfused liver extracts from
ASO-treated mice fed a 60% HFD for 8 weeks. n = 4–5/group. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test.

mice (Supplemental Figure 2, A–C). HMGCS2 ASO–treated mice
also exhibited normal serum free fatty acid (FFA) and TAG concentrations and a normal physiologic distribution of residual βOHB
and AcAc (Supplemental Figure 2, D–F). Interestingly, HMGCS2
ASO–treated mice displayed mild, but very consistently elevated,
blood glucose concentrations (160.9 ± 3.2 mg/dl vs. 145.0 ± 3.4
mg/dl in controls, n = 28–36/group, P = 0.0013), without changes
in serum insulin concentrations (Supplemental Figure 2, G and H).
5178
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Ketogenic insufficiency causes hepatic inflammation, injury, and
altered glucose metabolism in the setting of carbohydrate-replete overnutrition. To determine the effects of ketogenic insufficiency in
the context of overnutrition, mice previously receiving ASOs for 2
weeks while on a standard low-fat chow diet were then maintained
for 8 weeks on a 60% high-fat diet (HFD) commonly used to
induce hyperglycemia, hepatic steatosis, and inflammation in WT
mice. HMGCS2 immunoblots indicated that hepatic HMGCS2
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Figure 4. Mitochondrial acetyl-CoA and short- and medium-chain acylcarnitine accumulation in ketogenesis-insufficient mice. Mitochondrial respiration determined by the oxygen consumption rate of isolated mitochondria. State 2 (basal), state 3 (ADP), state 4 (oligomycin), and uncoupled (FCCP) respiration of mitochondria isolated from the livers of standard chow diet–fed ASO-treated mice using either (A) 10 mM pyruvate alone or (B) 10 mM pyruvate
with 5 mM malate as an anaplerotic substrate. n = 6–9/group. Blood acylcarnitines (μM) in (C) 40% and (D) 60% HFD-fed ASO-treated mice, determined by
MS/MS. n = 4–10/group. *P < 0.05, **P < 0.01, ***P < 0.001, by Student’s t test.

protein abundance was decreased by 93% within 2 weeks of ASO
treatment (Supplemental Figure 3A) and continued to decrease to
undetectable levels by the end of the 8-week HFD-feeding interval,
during which time ASO treatments were continued on a biweekly
basis (Supplemental Figure 3B). While serum TAG and FFA concentrations did not differ between groups of HFD-fed mice (Supplemental Figure 3, C and D), serum ketone body concentrations
were significantly decreased in HFD-fed HMGCS2 ASO–treated
mice (0.04 ± 0.02 mM vs. 0.26 ± 0.03 mM, P < 0.0001, n = 8–10/
group; Supplemental Figure 3E). After 8 weeks of HFD feeding,
we found that control and HMGCS2 ASO–treated mice exhibited mildly increased hepatic TAG concentrations (Figure 2A).
As expected, serum alanine aminotransferase (ALT) activity, a
circulating biomarker of hepatocellular injury, was not elevated
in HFD-fed control mice, given the relatively brief duration of
the HFD (Figure 2B). Conversely, HFD feeding increased serum
ALT activity by nearly 4-fold in HMGCS2 ASO–treated mice compared with mice maintained on a standard chow diet (223.5 ± 37.7
U/l vs. 61.2 ± 4.0 U/l in chow-fed HMGCS2 ASO–treated mice,
n = 4–5/group, P < 0.0001) and by 3-fold compared with the HFDfed control mice (223.5 ± 37.7 U/l vs. 74.3 ± 6.1 U/l in control mice,
n = 4/group, P < 0.0001; Figure 2B). Blinded histopathologic
evaluation of liver tissue from ketogenesis-insufficient mice fed
an HFD revealed evidence of injury, including panacinar inflam-

matory infiltrates and acidophil bodies (dying hepatocytes). We
did not observe these findings in livers from HFD-fed control
ASO-treated mice or chow-fed HMGCS2-deficient mice (Figure
2C). Livers of HFD-fed HMGCS2 ASO–treated mice also exhibited increased numbers of sinusoidal macrophages, as confirmed
by F4/80 immunohistochemical staining (80.5 ± 6.1 vs. 49.3 ± 3.2
F4/80+ cells/×20 field, P < 0.001, n = 5 fields/liver from 3 livers/
group; Figure 2D), and increased evidence of stellate cell activation, as indicated by anti–smooth muscle actin (SMA) immunostaining (8.2 ± 1.0 vs. 3.4 ± 0.6 SMA+ cells/×10 field, P < 0.001,
n = 19 fields/liver from 3 livers/group; Figure 2E). These results
indicate that ketogenic insufficiency in the setting of overnutrition
accelerates a pronounced NASH-like phenotype.
To determine the metabolic effects of ketogenic insufficiency
in the setting of overnutrition, we monitored blood glucose concentrations during the course of HFD administration. While
blood glucose levels were higher in HMGCS2 ASO–treated
mice at the onset of HFD feeding, glycemia began to decline in
these mice after 5 weeks of maintenance on this diet (Figure 3,
A and B). HFD-fed HMGCS2 ASO–treated mice also gained significantly less weight than did control mice (final weight after
HFD feeding: 26.8 ± 0.7 g vs. 30.3 ± 1.2 g in controls, P = 0.019,
n = 8–10/group) and ingested fewer calories (9.96 ± 0.3 kcal/
mouse/day vs. 12.9 ± 0.3 kcal/mouse/day in controls, P < 0.0001,
jci.org   Volume 124   Number 12   December 2014
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Figure 5. Altered DNL signatures in ketogenesis-insufficient mice. (A) Transcript abundances of DNL mediators in livers from ASO-treated mice. n = 5–10/
group. Srebp1c, sterol regulatory element–binding protein 1c; Chrebp1, carbohydrate-responsive element-binding protein 1; Fasn, fatty acid synthase; Acc1,
acetyl-CoA carboxylase; Scd1 and Scd2, stearoyl-CoA desaturase 1 and 2. (B) XCMS Online cloud plot of 495 dysregulated features in HMGCS2 ASO–treated livers perfused with [13C]pyruvate and [13C]lactate compared with those of control livers. The radius (upregulated and downregulated features relative to controls
are green and red, respectively) and shading darkness of each circle are proportional to each circle’s fold-change and P value, respectively. n = 4/group.
(C) Schematic adapted from the KEGG (refs. 38, 39), depicting the 14- and 16-carbon-long intermediates produced during fatty acid synthesis. Species putatively identified as features that are significantly enriched in HMGCS2 ASO–perfused livers are highlighted in green. (D) Untargeted LC/MS metabolomics identification and quantification of total abundance of long-chain acyl-CoA species in the livers of ASO-treated mice perfused with [13C]pyruvate and [13C]lactate.
n = 4/group. (E) Quantification of fractional 13C enrichment of glutamate from [13C]pyruvate determined by NMR in extracts of perfused livers of ASO-treated
mice. n = 7–8/group. (F) Relative acetyl-CoA ion counts in the livers of ASO-treated mice perfused with lactate and pyruvate as measured by LC/MS.
n = 4/group. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test or 2-way ANOVA, as appropriate, versus HMGCS2 ASO–treated mice, or as indicated.

n = 8–10 mice/group over 16 measurements of food intake;
Figure 3, C and D). However, decreased glycemia in ketogenesis-insufficient mice was not entirely attributable to decreased
caloric intake, because the capacity to support de novo glucose
production from [13C]pyruvate was decreased 4-fold in perfused
livers of HFD-fed HMGCS2 ASO–treated mice (1.8 ± 0.3% vs.
7.3 ± 1.1% fractional enrichment as [13C]glucose in controls,
P = 0.0009, n = 4–5/group; Figure 3E). While the total hepatic
5180

jci.org   Volume 124   Number 12   December 2014

glucose pool was expanded in perfused livers of HFD-fed
HMGCS2 ASO–treated mice (Figure 3F), de novo 13C-labeling of glucose from [13C]pyruvate was markedly diminished in
HFD-fed HMGCS2 ASO–treated livers (3.9 ± 1.7 pmol vs. 10.4
± 0.9 pmol [13C]glucose produced/mg of tissue in controls,
P = 0.016, n = 4–5/group; Figure 3G). Similarly to the responses
to the 60% HFD, HMGCS2 ASO–treated mice maintained on a
distinct 40% fat/sucrose-enriched diet for 8 weeks also exhib-
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Figure 6. Hepatic metabolic reprogramming in ketogenesis-insufficient mice. (A) Quantification of 13C enrichment of glucose from [13C]pyruvate and total
glucose concentrations (pmol/mg tissue) (B) determined by NMR in liver extracts of standard chow diet–fed ASO-treated mice perfused with the indicated
substrates. n = 7–8/group. (C) Relative transcript abundances of key mediators of fatty acid oxidation and gluconeogenesis in livers from standard chow
diet–fed ASO-treated mice. n = 8–10/group. Ppara, peroxisome proliferator–activated receptor α; Ppargc1a, peroxisome proliferator–activated receptor γ
coactivator 1-α; Acox1, acyl-CoA oxidase; Cpt1a, carnitine palmitoyl transferase 1-α; Acadm, medium-chain acyl-CoA dehydrogenase; Fgf21, fibroblast growth
factor 21; Me2, malic enzyme 2; Pck1, phosphoenol pyruvate carboxykinase; G6pc, glucose-6-phosphatase. (D) Quantification of total α-KG (nmol/mg tissue),
(E) succinate (pmol/mg tissue), and (F) total glutamate concentrations (nmol/mg tissue) determined by NMR in liver extracts of standard chow diet–fed
ASO-treated mice perfused with the indicated substrates. n = 7–8/group. (G) Concentrations of oxidized, reduced, and total nicotinamide adenine dinucleotide (NAD+, NADH, and NADt, respectively; nmol/g tissue) as well as the ratio of NAD+/NADH levels in the livers of standard chow diet–fed ASO-treated mice
perfused with lactate and pyruvate or (H) with lactate and pyruvate in the presence of octanoic acid. n = 4–6/group. *P < 0.05, **P < 0.01, ***P < 0.001 by
Student’s t test or 2-way ANOVA, as appropriate, versus HMGCS2 ASO–treated mice, or as indicated.

ited decreased weight gain, caloric intake, body fat percentages, and blood glucose concentrations (Supplemental Figure
4, A–D). Ketogenesis-insufficient mice fed a 40% HFD also exhibited hepatic steatosis equivalent to that of control HFD-fed mice,
modestly increased serum ALT activity, and microgranuloma formation and inflammatory infiltrates in the liver (Supplemental Fig-

ure 5, A–C). Importantly, we found that both the elevation of serum
ALT activity and the degree of histopathologic evidence of hepatic
inflammation were diminished in HMGCS2 ASO–treated mice fed
a 40% HFD compared with those fed a 60% HFD, suggesting that
chronic exposure to excess dietary fat drives the NASH-like phenotype observed in ketogenesis-insufficient mice.
jci.org   Volume 124   Number 12   December 2014
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Figure 7. Replenishing CoASH precursors restores gluconeogenesis and TCA cycle intermediate abnormalities in the livers of ketogenesis-insufficient
mice. (A) CoASH (pmol/mg tissue) concentrations in the livers of unperfused standard chow diet–fed ASO-treated mice or in livers perfused with the indicated substrates. n = 3–8/group. (B) Pantothenate kinase 1a and 1b (Pank1a and Pank1b) relative mRNA abundance in the livers of standard chow diet–fed
ASO-treated mice. n = 8–10/group. (C) Gluconeogenesis in perfused livers of standard chow diet–fed ASO-treated mice perfused with either [13C]lactate,
[13C]pyruvate, octanoic acid, cysteine, and pantothenic acid for 15 minutes (Preperfusion–) or preperfused with CoASH precursors for 45 minutes with
unlabeled lactate, pyruvate, cysteine, and pantothenic acid followed by 15 minutes of perfusion with [13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and
pantothenic acid. (D) α-KG (nmol/mg tissue), (E) glutamate (nmol/mg tissue), (F) succinate (pmol/mg tissue), and (G) CoASH (pmol/mg tissue) concentrations in the same livers as in C. n = 5–7/group. *P < 0.05, **P < 0.01, ***P < 0.001, by 2-way ANOVA.

Ketogenic insufficiency increases acyl-CoA synthesis. Abnormal
hepatic glucose metabolism in HFD-fed ketogenesis-insufficient
animals suggested reprogramming of intermediary metabolism.
Because the major conduits for acetyl-CoA in hepatic mitochondria include: (a) ketogenesis, (b) transport to the cytoplasm via
the citrate shuttle to serve as a substrate for sterol or fatty acid
synthesis, (c) terminal oxidation in the TCA cycle, or (d) ultimate
conversion to acetylcarnitine (19), we performed 3 independent
5182
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experiments to test the hypothesis that insufficient ketogenesis
stimulates the procession of acetyl-CoA through the latter 3 nonketogenic pathways. First, to determine whether the acetyl-CoA
fate was altered in hepatic mitochondria of ketogenesis-insufficient mice, we performed respiration studies on isolated hepatic
mitochondria from ASO-treated animals fed a standard low-fat
chow diet. While respiration rates using fatty acids (palmitoyl-Lcarnitine or octanoate) as oxidative substrates were not impaired
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Figure 8. Model of hepatic maladaptation to ketogenic insufficiency. Under homeostatic conditions (left panel), mitochondrial acetyl-CoA can be channeled to ketogenesis, terminal oxidation in the TCA cycle, or exported to the cytoplasm for DNL. In the setting of ketogenic insufficiency (middle panel), DNL
and gluconeogenesis from pyruvate are increased. Loss of the ketogenic conduit stimulates increased acetyl-CoA disposal through the TCA cycle, increasing gluconeogenesis and export to the cytoplasm for DNL. These changes partly reflect the alterations encountered in NAFLD, in which the liver exhibits
increased esterification to and lipolysis from lipid droplets, increased β-oxidation of fatty acids, increased terminal oxidation, and increased gluconeogenesis, but diminished ketogenesis relative to the availability of fat. In the extreme circumstance of ketogenic insufficiency and a high-fat load (right panel),
β-oxidation–derived acetyl-CoA sequesters CoASH. This disrupts the TCA cycle, and in the setting of increased DNL, ultimately triggers hepatic injury and
inflammation. Arrow thicknesses reflect relative changes through enzymatic reactions among panels rather than between reaction pathways within a panel.
While proportional contributions of pyruvate carboxylase (PC) and PDH fluxes to the pyruvate fate are dynamic in states of feeding and fasting, both fluxes
occur simultaneously in both physiological states (86, 87) and are likely to be influenced by insufficient ketogenesis. ME, malic enzyme.

in hepatic mitochondria isolated from ketogenesis-insufficient
animals (data not shown), oxygen consumption using pyruvate
alone was markedly impaired: respiratory rates were diminished
31% in state 2 (basal proton leak), 62% in state 3 (ADP-stimulated),
49% in state 4 (ATP synthase–inhibited), and 65% during uncoupled (maximal) respiration (Figure 4A). These results suggested
relatively impaired pyruvate oxidation in ketogenesis-insufficient
mice. Pyruvate dehydrogenase (PDH), the enzyme that decarboxylates pyruvate to form acetyl-CoA for terminal oxidation in
the TCA cycle, is inhibited by increased acetyl-CoA concentrations (35). The addition of anaplerotic malate, which can facilitate acetyl-CoA export as citrate upon its conversion to oxaloacetate, normalized the capacity of hepatic mitochondria isolated
from ketogenesis-insufficient mice to oxidize pyruvate (Figure
4B). Independent respiration studies using malate alone revealed
minimal oxygen consumption that did not differ between groups
(data not shown). These results suggest that while the respiratory
function of isolated mitochondria from ketogenesis-insufficient
mice is intact, an anaplerotic substrate is required to facilitate
cytoplasmic export of excess acetyl-CoA as citrate to relieve inhibition of pyruvate oxidation.
Second, we quantified circulating acylcarnitine concentrations and observed that short- and medium-chain acylcarnitine
concentrations, but not those of long-chain acylcarnitines, were
significantly increased in HMGCS2 ASO–treated mice compared
with controls fed either a 40% or 60% HFD, but not a standard
low-fat chow diet (Figure 4, C and D; See Supplemental Tables
1–3 for full acylcarnitine profiles for chow-fed, 40% HFD-fed, and
60% HFD-fed mice). These results suggest that ketogenic insufficiency is unlikely to cause an overt impairment of β-oxidation,
but that the supply of short-chain acyl-CoAs exceeds the capacity

of the TCA cycle to dispose of them. Nonetheless, carnitine esters
provide another mechanism for short- and medium-chain acylCoA disposal through nonketogenic mechanisms.
A third line of investigation comprehensively profiled the fate
of acetyl-CoA in an unbiased manner. mRNA abundances of key
encoded mediators of de novo lipogenesis (DNL) were increased in
the livers of ketogenesis-insufficient animals, including significant
increases in Srebp1c, Chrebp1, and Scd2, and strong trends toward
increases in Fasn and Acc1 (Figure 5A). To map the full scope of the
metabolic fates of acetyl-CoA, we perfused the livers of standard
chow diet–fed ketogenesis-insufficient and control animals with a
buffer containing [13C]pyruvate (and its redox partner [13C]lactate)
for 15 minutes and analyzed extracts of these samples with a liquid
chromatography/mass spectrometry-based (LC/MS-based) untargeted metabolomics platform (36, 37). We used [13C]pyruvate to
generate a mitochondrial pool of labeled [13C]acetyl-CoA, whose
downstream fates could then be assayed by detecting 13C enrichment in metabolites using LC/MS, comparing metabolite abundances in ketogenesis-insufficient animals versus those in controls.
This analysis revealed that ketogenic insufficiency in the livers of
mice fed a standard chow diet resulted in altered levels of 495 features (i.e., peaks in the LC/MS data) of a total of 35,506 detected
(fold-change >20, P value < 0.01; Figure 5B and Supplemental
Table 4). Remarkably, all but 3 of these 495 features were upregulated in the livers from ketogenesis-insufficient mice relative to
those detected in control livers, suggesting that the vast majority
of revealed features can be attributed to alterations of metabolite
pool sizes rather than the emergence of new fates for [13C]pyruvate.
Given the alterations we identified in mRNAs of DNL mediators, metabolites in the fatty acid elongation pathway were of
particular interest. Thus, we searched all features of 13C-labeled
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acyl-CoA species produced in the fatty acid elongation pathway
described in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (38, 39) and identified 14 features whose mass-to-charge
value matched 1 or more of these species (Supplemental Table
5). The summed ion count of each of these acyl-CoA groups, representing the total abundance of a species in all of its observed
labeled forms, was markedly increased in HMGCS2-deficient livers, suggesting increased flux through the DNL pathway (Figure 5,
C and D). To confirm that these identified acyl-CoA species were
not differentially labeled by [13C]pyruvate, bioinformatics analysis
using software that we recently developed (40) revealed that these
compounds were not labeled differently in ketogenesis-insufficient animals compared with those in controls, again supporting
that augmented acyl-CoA pools cannot simply be attributed to
increased labeling, but instead indicate increased pool sizes. Moreover, terminal oxidation of [13C]pyruvate in the TCA cycle was relatively diminished in the livers of ketogenesis-insufficient animals,
as revealed by quantification of the fractional 13C enrichment of
glutamate from [13C]pyruvate by NMR (12.8 ± 1.9% 13C enrichment
of glutamate vs. 20.1 ± 2.7% in controls, n = 7–8/group, P < 0.05;
Figure 5E); 13C enrichment of glutamate serves as a quantitative
surrogate for [13C]acetyl-CoA terminal oxidation (41). However, we
found that steady-state acetyl-CoA concentrations in whole liver
extracts were not altered in ketogenesis-insufficient animals (Figure 5F). Collectively, these findings indicate that insufficient ketogenesis triggers a redistribution of the total mitochondrial acetylCoA pool toward export and de novo lipid synthesis.
Ketogenic insufficiency sequesters free CoASH. To better understand the shift from hyperglycemia in chow-fed ketogenesis-insufficient mice to hypoglycemia upon high-fat feeding, we quantified
gluconeogenesis from [13C]pyruvate in the presence or absence of
octanoic acid in perfused livers of ASO-treated mice fed a standard low-fat chow diet. Octanoic acid is a medium-chain fatty acid
that enters the mitochondrial matrix independently of carnitine
palmitoyltransferase 1 (CPT1) and rapidly stimulates mitochondrial β-oxidation and gluconeogenesis (19). Consistent with the
observation of hyperglycemia in standard chow diet–fed HMGCS2
ASO–treated mice (Supplemental Figure 2G), we found that basal
gluconeogenesis from pyruvate in the absence of octanoic acid
was increased in the livers of ketogenesis-insufficient animals
(15.2 ± 2.1% 13C enrichment of glucose vs. 9.0 ± 1.0% in controls,
n = 7–8/group, P = 0.015; Figure 6A). Because total hepatic glucose concentrations did not differ between groups (Figure 6B),
the increased enrichment reflects increased production from
pyruvate. As expected, the addition of unlabeled octanoic acid to
the perfusion buffer stimulated gluconeogenesis in the livers of
control animals (Figure 6A, white bars), but in contrast, HMGCS2
ASO–treated livers perfused with octanoic acid did not increase
gluconeogenesis and, in fact, exhibited decreased 13C-glucose
enrichment compared with that seen in control livers (11.8 ± 1.7%
13
C enrichment of glucose vs. 17.6 ± 1.3% in controls, n = 7–8/group,
P = 0.018; Figure 6A), without altering total glucose pools (Figure
6B). We observed the inability of octanoic acid to stimulate glucose production in HMGCS2 ASO–treated livers despite increased
mRNA abundances of Ppara, Aco, Cpt1a, Ppargc1a, Pck1, and Me2
and normal mRNA abundances of Acadm, Fgf21, and G6Pc in liver
(Figure 6C), suggesting that a metabolic mechanism, rather than
5184
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insufficient expression of the enzymatic mediators of fatty acid
oxidation and gluconeogenesis, underlies the observed defect in
fatty acid–stimulated glucose production in the setting of ketogenic insufficiency.
Because the induction of gluconeogenesis by fatty acids is
dependent on the NADH and ATP generated through the TCA
cycle (16, 42, 43), we hypothesized that the failure of mitochondrial
fatty acids to stimulate gluconeogenesis in the absence of ketogenesis could be mechanistically linked to a failure to couple β-oxidation of fatty acids to their terminal oxidation via the TCA cycle. To
determine whether there were abnormalities of TCA cycle function in the livers of HMGCS2 ASO–treated mice, we used NMR to
quantify TCA cycle intermediate–pool concentrations in perfused
livers of control and HMGCS2 ASO–treated mice. While tissue
α-ketoglutarate (α-KG) concentrations were normal in the livers
perfused in the absence of octanoate, inclusion of this fatty acid in
the perfusion buffer increased concentrations of α-KG by 2-fold in
HMGCS2 ASO–treated livers (0.75 ± 0.08 nmol/mg tissue vs. 0.34
± 0.08 nmol/mg tissue in control livers perfused with octanoate,
n = 7–8/group, P = 0.0032; Figure 6D). Perfusion with octanoic acid
also increased hepatic concentrations of glutamate, an equilibrium
partner of α-KG, by 2-fold, but significantly decreased hepatic succinate concentrations by 43% in HMGCS2 ASO–treated livers (99.9
± 12.9 pmol/mg tissue vs. 162.8 ± 20.1 pmol/mg tissue in controls,
P < 0.01, n = 7–8/group; Figure 6, E and F). These derangements of
TCA cycle intermediate concentrations were not linked to redox
potential alterations, as NAD+, NADH, NADt concentrations, and
NAD+/NADH ratios in ketogenesis-insufficient livers perfused in the
absence (Figure 6G) or presence (Figure 6H) of octanoate were not
different from those of control animals. Taken together, these data
suggest that ketogenic insufficiency disrupts TCA cycle homeostasis
and gluconeogenesis through mechanisms independent of altered
redox potential.
The NMR findings from perfused livers of ketogenesis-insufficient mice suggest a block at the TCA cycle reaction catalyzed
by the α-KG dehydrogenase complex (OGDC). Since intrinsic
OGDC activity was normal in isolated mitochondrial respiration
assays using glutamate as a substrate (data not shown), the redox
potential was normal in perfused livers, and oxidative decarboxylation of α-KG to succinyl-CoA requires free CoASH, we tested
the hypothesis that CoASH becomes limiting in ketogenesisinsufficient livers exposed to excess fat by quantifying CoASH
concentrations in unperfused and perfused livers of ASO-treated
mice. While HMGCS2 ASO treatment did not alter CoASH concentrations in unperfused livers of standard chow diet–fed mice
or in livers perfused in the absence of octanoate, hepatic CoASH
concentrations were decreased by 60% in HMGCS2 ASO–treated
livers perfused with octanoic acid (40.7 ± 14.4 pmol/mg tissue vs.
106.6 ± 24.3 pmol/mg tissue in controls, P = 0.035, n = 8/group;
Figure 7A). The fatty acid–induced depletion of CoASH observed
in HMGCS2 ASO–treated livers occurred despite normal expression of Pank1a and increased expression of Pank1b (1.0 ± 0.02
vs. 2.5 ± 0.6, P = 0.04, n = 8–10/group), whose products phosphorylate pantothenic acid in the first step of de novo CoASH
biosynthesis (Figure 7B). Consistent with the octanoate-induced
derangements of TCA cycle intermediates and CoASH depletion
in livers of standard chow diet–fed HMGCS2 ASO–treated mice,
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unperfused livers of HMGCS2 ASO–treated mice fed a 60%
HFD displayed increased glutamate concentration (2.6 ± 0.4 vs.
1.1 ± 0.1 nmol/mg tissue in controls, P = 0.018, n = 4–5/group), a
trend toward decreased succinate concentration, and decreased
hepatic CoASH concentration (28.4 ± 11.5 pmol CoASH/mg tissue vs. 103.1 ± 32.6 in controls, P = 0.049, n = 8/group; Supplemental Figure 6, A–C). Taken together, these results suggest that
ketogenic insufficiency in the setting of high-fat delivery depletes
free CoASH and thereby impairs TCA cycle function, which further inhibits entry of acetyl-CoA and also favors increased accumulation of short-chain acylcarnitines.
To determine whether supplementation of the CoASH precursors pantothenic acid (vitamin B5) and cysteine could restore
glucose production and normalize TCA cycle intermediate concentrations in HMGCS2 ASO–treated livers, we perfused the livers of HMGCS2-deficient and control animals with exogenous
octanoate and CoASH precursors. While inclusion of pantothenic
acid and cysteine with [13C]lactate, [13C]pyruvate, and unlabeled
octanoic acid during a 15-minute perfusion failed to normalize
gluconeogenesis in HMGCS2 ASO–treated livers (Figure 7C, left),
prolonged repletion of CoASH precursors by perfusing independent livers with pantothenic acid and cysteine for 45 minutes
prior to perfusion with [13C]lactate and [13C]pyruvate, unlabeled
octanoic acid, pantothenic acid, and cysteine for 15 minutes
normalized 13C-glucose enrichment (Figure 7C, right). Total
hepatic glucose concentrations did not differ between control
and HMGCS2 ASO–treated livers in either perfusion experiment
(Supplemental Figure 7). Moreover, preperfusion with CoASH
precursors attenuated the expansion of the α-KG and glutamate
pools in HMGCS2 ASO–treated livers, with preperfused HMGCS2
ASO–treated livers exhibiting a 29% decrease in α-KG concentrations and a 43% decrease in glutamate concentrations compared
with those in HMGCS2 ASO–treated livers that were not preperfused with CoASH precursors (n = 5–7/group, P < 0.05 for α-KG,
and P < 0.001 for glutamate; Figure 7, D and E). Inclusion of pantothenic acid and cysteine also normalized succinate concentrations in the livers of HMGCS2 ASO–treated mice, irrespective of
the length of the perfusion (Figure 7F). Finally, CoASH precursor
supplementation with either method of perfusion normalized the
steady-state concentrations of free CoASH in the livers of ketogenesis-insufficient mice compared with those in control livers
(Figure 7G). Taken together, these results mechanistically link
the HFD-induced hypoglycemia and fat-induced impairment of
hepatic gluconeogenesis we observed in ketogenesis-insufficient
mice to CoASH depletion and inhibition of the α-KG dehydrogenase reaction of the TCA cycle.

Discussion

Hepatic ketogenesis is activated when fatty acids are plentiful, carbohydrates are in short supply, and/or circulating insulin concentrations are low (17–21). This spillover pathway converts β-oxidation–derived acetyl-CoA, produced in excess of the hepatocyte’s
own energy needs, into ketone body intermediates, thus diverting
carbon away from the hepatic TCA cycle and providing extrahepatic tissues with a readily oxidized fuel source. This paradigm
forms an “altruistic” model of ketone body metabolism, in which
the hepatocyte shares “precatabolized” energy obtained from fatty
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acids with other organs that may require it, particularly in states
of diminished carbohydrate availability. However, this model neither accounts for the hepatocyte’s need to support ketogenesis for
its own metabolic homeostasis, nor considers the importance of
basal hepatic ketogenesis in physiological states that are not considered “ketogenic” (i.e., carbohydrate restricted). Ours are the
first studies to our knowledge to demonstrate a critical role for
hepatic ketogenesis in the normal absorptive state and in prevention of metabolic decompensation in the setting of overnutrition.
We found that when ketogenic capacity is markedly impaired,
an HFD triggers a cascade of events that culminates in hepatic
injury and inflammation. These observations are underscored
by our recent studies of germline SCOT-KO mice, which cannot
terminally oxidize ketone bodies in any tissue. These mice exhibit
hyperketonemic hypoglycemia and die within 48 hours of birth in
a manner that phenocopies human sudden infant death syndrome
(SIDS) (32). Despite the fact that SCOT is normally excluded from
hepatocytes, livers of SCOT-KO mice develop abnormalities of
hepatic fatty acid oxidation, pyruvate metabolism, redox potential, and even ketogenesis (22, 33). In stark contrast to the severe
metabolic derangements and SIDS-like phenotype observed in
neonatal SCOT-KO mice, mice that cannot oxidize ketone bodies
selectively within neurons, cardiomyocytes, or skeletal myocytes,
which comprise the 3 greatest consumers of ketone bodies, survive
the neonatal period and starvation in adulthood (34). Together,
these results indicate that coordination of ketogenesis and ketone
body oxidation may be of greater importance to preserve the
dynamic intermediary metabolic network in the liver than it is to
provide energy to extrahepatic tissues.
Our data are consistent with a model (Figure 8) in which the
metabolic consequences of ketogenic insufficiency occur along a
continuum of maladaptive consequences. On a standard diet and
in the absence of a high lipid load, the modest amount of acetylCoA generated from endogenous fats that would normally proceed
through ketogenesis is instead terminally oxidized in the TCA cycle,
generating the ATP and NADH to support increased gluconeogenesis from pyruvate, thereby predisposing to mild hyperglycemia. In
addition, the total hepatic mitochondrial pool of acetyl-CoA, which
is predominantly derived from β-oxidation of acyl-CoAs and by
decarboxylation of pyruvate, is maintained at a homeostatic concentration by eventual conversion to acetylcarnitine and by exportation
as citrate for synthesis of de novo lipids. Given that gluconeogenesis is indirectly stimulated by mitochondrial acetyl-CoA through
allosteric activation of pyruvate carboxylase (44), adult-onset loss
of ketogenesis may reset the basal rate of gluconeogenesis through
a shift toward increased mitochondrial acetyl-CoA. Therefore,
even in the nonlipolytic absorptive state, in which dietary carbohydrates are abundant, hepatic ketogenesis influences glycemia and
hepatic lipid metabolism through modulation of acetyl-CoA fates.
These experimental conditions, in which ketogenesis is severely
deficient but exogenous fat delivery is low, may be representative
of more clinically relevant states in which ketogenesis is modestly
suppressed, but exogenous fat delivery (from intake) is elevated.
Acetyl-CoA metabolism has recently emerged as a key regulator of
numerous cellular processes and signaling pathways, and acetylCoA has different roles depending on its site of synthesis or accumulation. Cytosolic and/or nuclear acetyl-CoA regulate protein
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acetylation (45, 46), autophagy (47, 48), and histone acetylation and
subsequent transcriptional changes (49, 50). Future experiments
will explore the scope of signaling consequences of insufficient
ketogenesis, how altered acetyl-CoA metabolism may mediate
those effects, and how discrete acetyl-CoA pools target distinct
fates based on the original source of acetyl-CoA. Because the retention time window harboring the majority of dysregulated LC/MS
features in the livers of ketogenesis-insufficient animals included a
large number of lipophilic molecules, these approaches may reveal
previously unsuspected connectivity among hepatic ketogenesis,
acetyl-CoA, lipid metabolism, and cell signaling.
The convergence of ketogenic insufficiency with either acute
delivery of fatty acids or chronic exposure to a “nonketogenic”
(not carbohydrate-restricted) HFD results in additional metabolic
sequelae (Figure 8, right) that uncouple increased fat availability
from increased gluconeogenesis through mechanisms that can
be linked to sequestration of free CoASH, a critical by-product of
ketogenesis. Therefore, despite presumably increased allosteric
activation of pyruvate carboxylation, gluconeogenesis becomes
impaired through mechanisms that can be linked to a diminished
availability of CoASH. CoASH liberated by ketogenesis is critical
in states of high-fat delivery, in part by serving as a substrate for
the α-KG dehydrogenase reaction, to support homeostatic TCA
cycle function, which in hepatocytes is a key regulator of gluconeogenesis. Intriguingly, the total hepatic triacylglycerol pool did not
expand in the livers of HFD-fed ketogenesis-insufficient animals
compared with that observed in controls, suggesting either relative limitation of substrate (e.g., glycerol), impairment of cytoplasmic acylglycerol transferase or phosphatidate phosphatase activity, or entry of acyl chains into other synthetic pathways.
Ketogenesis-insufficient mice fed an HFD developed steatosis
equivalent to that seen in controls, but only ketogenesis-insufficient
mice developed severe inflammation, suggesting that of the 2 major
NAFLD subtypes, simple steatosis and NASH, impaired ketogenesis may be an important determinant of NASH (1). Other forms of
hepatocellular injury are also associated with decreased CoASH concentrations. In acute acetaminophen toxicity, CoASH levels decrease
simultaneously with decreasing HMGCS2 enzymatic activity (51,
52). Potentially fatal valproic acid therapy–induced hepatic dysfunction, which is associated with impaired β-oxidation of fatty acids
and ketogenesis due to sequestration of CoASH into poorly metabolized valproyl CoA, can be prevented by administration of CoASH
precursors (53, 54). In rodents, hepatic CoASH concentrations
decrease in response to an HFD (55), while the concentration of pantothenic acid actually increases (56), suggesting that hepatic CoASH
homeostasis is dysregulated in obesity. De novo CoASH synthesis is
required for life in mice, and impaired CoASH synthesis is associated
with fasting-induced hepatic steatosis (57, 58). CoA sequestration,
toxicity, or redistribution (CASTOR) encompasses hereditary and
acquired diseases of impaired CoASH liberation, including deficiencies of hepatic ketogenesis (59). Despite the increasing burden
of evidence for the contribution of CoASH homeostasis to hepatic
function, the role of therapies that support de novo CoASH synthesis
in obesity and NAFLD remains relatively unexplored.
HMGCS2 has been proposed to possess a “moonlighting”
role as a transcriptional regulator that translocates to the nucleus
and serves as a coactivator for a master transcriptional regula5186
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tor of fatty acid oxidation, peroxisome proliferator–activated
receptor α (PPARα) (60, 61). In at least 1 immortalized hepatoma
cell line, HMGCS2 expression was required for fatty acid oxidation (62). In contrast, our observations reveal a robust induction of several classical PPARα targets in the absence of hepatic
HMGCS2, and 2 lines of evidence support robust fatty acid oxidation in the livers of HMGCS2-deficient mice: (a) long-chain
acylcarnitines did not accumulate, and (b) the contribution of
pyruvate to the acetyl-CoA oxidized in the TCA cycle was relatively diminished. Moreover, the increased gluconeogenesis we
observed in the livers of ketogenesis-insufficient animals under
low-fat-diet conditions strongly suggests normal or elevated
TCA cycle flux. Together, these data indicate an increase in the
relative contribution of endogenous fatty acids to the TCA cycle
and are consistent with metabolic flux that is driven primarily
by the principles of mass action and enzymatic allostery, with
coordinated responses at the level of gene expression that reflect
adaptations to diminished disposal of acetyl-CoA through ketogenesis. Whether HMGCS2 serves as a PPARα coactivator in vivo
remains to be determined, as does whether the prospective ligands produced via DNL in ketogenesis-insufficient animals serve
as potential PPARα activators (63).
Genome-wide association and exome sequencing studies
have revealed relationships between numerous genes encoding mediators of lipid metabolism and NAFLD/NASH (64, 65).
Variations in the genes encoding ketogenic mediators, including
HMGCS2, HMG-CoA lyase, and βOHB dehydrogenase, have
not yet emerged as independent predictors of liver pathology
or diabetes. While HMGCS2 deficiency is very rare in humans,
total HMGCS2 enzymatic deficiency is associated with pediatric hypoketonemic hypoglycemia and hepatic steatosis (66–71).
Importantly, our studies of neonatal mice revealed that partial
loss of HMGCS2 activity caused marked hepatic steatosis vastly
out of proportion to the diminution in neonatal ketosis, but did
not result in neonatal hypoglycemia or failure to thrive. These
findings raise the possibility that genetic polymorphisms yielding
insidious and subtle ketogenic defects could latently predispose
to fatty liver disease and attest to the critical fine-tuning role that
hepatic ketogenesis plays in the regulation of hepatic glucose and
lipid metabolism.
No current pharmacological therapies directly treat NAFLD
or NASH, which are managed instead through lifestyle modifications such as weight loss and treatment of dyslipidemia and
hyperglycemia (72). A variety of agents are at various stages of
investigation, including compounds targeting oxidative stress,
nuclear receptor activators, insulin sensitizers, modifiers of dyslipidemias, and immunomodulatory agents (3, 6). Ketogenesis has
not yet been considered as a therapeutic target. Obese humans
and mice exhibit diminished whole-body ketone body turnover
(26, 29). Furthermore, circulating ketone body concentrations
are generally decreased in obese humans (24, 25, 27) and serve as
predictive biomarkers for conversion to type 2 diabetes in patients
with impaired fasting glucose (73). Compared with BMI-matched
individuals, obese patients with NAFLD exhibit increased hepatic
glucose production and TCA cycle flux without augmented ketogenesis (28). DNA methylation, nuclear receptor–mediated transcriptional activation, and reversible succinylation, acetylation,
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and phosphorylation all exert multitiered transcriptional and
posttranslational regulation of Hmgcs2 expression and HMGCS2
enzymatic activity to coordinate ketogenesis during diverse physiologic contexts (17, 74–78). Pharmacological approaches that
regulate enzymatic mediators of lysine deacylation (45) may represent a promising avenue for modulating HMGCS2 and ketogenesis, which may serve as a novel therapeutic target in fatty liver
disease and obesity.

Methods

Further information can be found in the Supplemental Methods.
Animals. All adult mice studied were males on a C57BL/6N X
C57BL/6J hybrid background. For neonatal experiments, both sexes
were studied. Unless otherwise noted, mice were maintained on a
standard low-fat chow diet, in which 13% of the calories were from
fat, 25% from protein, and 62% from carbohydrates (LabDiet 5053),
and were given autoclaved water ad libitum. Lights were off between
1800 and 0600 in a room maintained at 22°C. For all adult mouse
experiments, mice were housed on sawdust bedding in groups of 4
to 5. ASO treatment was initiated in 6-week-old mice by i.p. injection (25 mg/kg) with murine Hmgcs2-targeted ASOs (ISIS 191229;
5′-CTGTTTGTCACTGCTGGATG) or scrambled sequence control
ASOs (ISIS 141923; 5′-CCTTCCCTGAAGGTTCCTCC) biweekly
for 4 weeks. For HFD studies, after 2 weeks of ASO treatment, mice
were maintained for 8 weeks on either an HFD, in which 60% of calories were from fat, 20% from protein, and 20% from carbohydrates
(D12492; Research Diets), or, in separate cohorts, a diet (110290;
Harlan Teklad) in which 40.7% of calories were from fat (lard and
milk fat, 52% saturated, 41% monounsaturated, and 7% polyunsaturated [0% trans] fatty acids), 19% from protein, and 40.3% from
carbohydrates (sucrose, 183 g/kg and cornstarch, 140 g/kg), during
which time biweekly ASO administration continued. For the neonatal experiments, ASOs were administered (25 mg/kg) s.c. daily,
beginning on the second day of life and until P12. Pups were marked
on the abdomen daily with a permanent marker to enable longitudinal monitoring of body weight and blood glucose. Marking also
enabled control and HMGCS2 ASOs to be administered to different
pups within the same litter, thus minimizing inter-litter variance of
metabolic parameters.
Measurements of food intake, body weight, and body composition.
Food intake was monitored beginning on day 1 of ASO treatment
for each cage of mice. Food intake was measured biweekly for the
duration of each experiment and normalized to the number of mice
per cage and the number of days between measurements, which was
always 3 or 4 days. Mice were also weighed biweekly at the onset of
all experiments. Body weight and body composition were recorded
following a 4-hour fast (1000–1400), after which food was returned
immediately. The percentage of body fat and lean body mass was
quantified in awake adult animals using an EchoMRI instrument
(Echo Medical Systems).
Plasma metabolite quantification. Serum and blood metabolic
parameters were measured in samples collected following a 4-hour
fast, as described previously (31).
Tissue metabolite quantification. Hepatic TAG concentrations
were quantified biochemically using a Folch extract of liver, as
described previously (79). Tissue CoASH, NAD+, and NADH concentrations were measured in freeze-clamped and biopulverized
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liver tissue. For CoASH, approximately 75 mg of tissue was homogenized using a glass-on-glass dounce in ×10 volume of ice-cold deionized water. Homogenates were spun at 15,000 g for 20 minutes at
4°C. Supernatants were transferred to clean tubes on ice and were
then dehydrated using a rotary speed vacuum. Tissue pellets were
resuspended to 2 mg/μl, and 20 mg of tissue (10 μl) were loaded
into a 96-well plate for CoASH and long-chain acyl-CoA concentrations using an enzyme-linked colorimetric assay (BioVision).
NAD+(H) concentrations were measured using an enzyme-cycling
colorimetric assay (BioVision).
Histology. Immediately following sacrifice, liver specimens were
collected and fixed in 10% neutral buffered formalin (Fisher Scientific) or cryopreserved in optimal cutting temperature compound
(O.C.T.; Tissue-Tek).
Gene expression analysis. Quantification of gene expression was
performed by real-time reverse-transcriptase quantitative PCR
using the ΔΔCt approach, as previously described (31), normalizing
to Rpl32, using the primer sequences listed in Supplemental Table 6.
Immunoblotting. Immunoblots to detect HMGCS2 (rabbit antimHMGCS; Santa Cruz Biotechnology Inc.), HMGCS1 (rabbit antiHMGCS1; Thermo Fisher Scientific), and actin (rabbit anti-actin; Sigma-Aldrich) were performed as previously described (32).
Liver perfusions. Mice were fasted for 4 hours prior to perfusion,
with the exception of mice that were perfused after an overnight
fast as indicated in the Results. Ten minutes prior to each liver perfusion, mice received an i.m. injection of heparin (100 U). Mice
were then anesthetized with 10 μl of sodium pentobarbital (FatalPlus, 390 mg/ml) administered i.p. Once fully anesthetized (after
approximately 5 minutes), the abdomen was sprayed with 70%
ethanol, and the mouse was placed on a surgical platform within
a large reservoir to contain run-off buffer and body fluids. A transverse incision was made through the skin, fascia, and muscular
layers of the lower abdomen. A lateral sagittal incision was made
on each side of the body, exposing the abdominal contents. A second transverse incision was made inferiorly to the right kidney and
toward the dorsal aspect of the mouse to allow the perfusion buffer
and body fluids to drain from the abdomen. The portal vein was then
exposed by gently moving the intestines laterally toward the left
body wall. A suture needle was threaded under the portal vein and
tied loosely. Next, the portal vein was cannulated with a 24-gauge
catheter needle, the needle was withdrawn, and tubing with buffer
was reconnected to the catheter. The abdominal aorta and inferior
vena cava were cut, and the catheter was firmly tied into the portal
vein. Finally, the beating heart was exposed by cutting through the
diaphragm and thorax. The right atrium was cut to prevent recirculation of buffer to the liver and to terminate perfusion to the brain.
All livers were perfused with an oxygenated Krebs-Henseleit bicarbonate buffer (118 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 0.4
mM KH2PO4, 2.5 mM CaCl2, 1.22 mM MgSO4 -7•H2O, pH 7.4) and
warmed to 37°C with a counter-current heat-exchange circuit and
a recirculating water bath at a rate of 8 ml/minute using a peristaltic pump for 15 minutes, unless otherwise noted. At the end of the
perfusion, the liver was freeze-clamped and rapidly frozen in a bath
of liquid nitrogen. Tissue was stored at –80°C until further processing. For measurements of ketogenesis in perfused livers, the buffers
contained sodium [1,2,3,4-13C4]octanoate (0.2 mM), sodium lactate
(1.5 mM), and sodium pyruvate (0.15 mM). For all measurements
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of gluconeogenesis, the livers were perfused with sodium [3-13C]
lactate (1.5 mM) and sodium [3-13C]pyruvate (0.15 mM), and in a
subset of these experiments, unlabeled sodium octanoate (0.2 mM)
was included in the buffer (stable isotopes were obtained from Cambridge Isotope Laboratories). For the CoASH repletion experiments,
unlabeled pantothenic acid and L-cysteine were included in the perfusion buffer at 0.15 mM and 0.1 mM, respectively, in addition to
sodium [3-13C]lactate (1.5 mM), sodium [3-13C]pyruvate (0.15 mM),
and unlabeled sodium octanoate (0.2 mM). The livers preperfused
with CoASH precursors received unlabeled pantothenic acid (0.15
mM), Cys (0.1 mM), sodium lactate (1.5 mM), and sodium pyruvate
(0.15 mM) for 45 minutes before being switched to a buffer containing pantothenic acid (0.15 mM), cysteine (0.1 mM), sodium [3-13C]
lactate (1.5 mM), sodium [3-13C]pyruvate (0.15 mM), and unlabeled
sodium octanoate (0.2 mM) for 15 minutes.
NMR-based quantitative substrate fate mapping. Neutralized perchloric acid tissue extracts were prepared and profiled using 13C-edited
proton NMR, as described previously (32, 33).
Tandem MS analysis of blood acylcarnitines. Carnitine esters were
measured by scanning for the precursors of the common m/z 85 carnitine fragment in a reversed-phase LC protocol coupled to tandem MS
(MS/MS), as described previously (80).
Untargeted LC/MS profiling of perfused liver extracts. Livers
from control- and HMGCS2 ASO–treated mice were perfused
with sodium [3-13C]lactate (1.5 mM) and sodium [3-13C]pyruvate
(0.15 mM) as described above, then snap-frozen and pulverized.
Four replicates of each sample type consisting of 10 to 20 mg of
pulverized tissue were extracted with 1 ml of 2:2:1 acetonitrile
(ACN)/methanol/water, using the protocol previously described
by Ivanisevic et al. (37). Briefly, samples were resuspended in
solvent and subjected to repeated freeze-thaw cycles. Extracted
metabolites were recovered through evaporation of the solvent
and reconstituted in 100 μl of 1:1 ACN/water for LC/MS analysis.
Eight microliters of each extract was injected onto a Luna aminopropyl 3-μm, 150-mm × 1.0-mm internal-diameter column (Phenomenex) used in hydrophilic interaction liquid chromatography
(HILIC) mode on an Agilent 1260 HPLC system. Mobile-phase
compositions were: A = 95% water, 5% ACN, 10 mM ammonium
hydroxide, 10 mM ammonium acetate, pH 9.5; B = 95 % ACN, 5 %
water, with the gradient set at 100% B from 0 to 5 minutes, 100%
to 0% B from 5 to 50 minutes, and 0% B from 45 to 50 minutes.
The flow rate was 50 μl/minute. MS detection in the range of 30 to
1,500 m/z was performed on an Agilent 6540 quadrupole time-offlight (Q-TOF) instrument equipped with a Dual Agilent Jetstream
electrospray ionization (ESI) source operating in negative mode.
Source parameters were set at: gas temperature = 300°C, drying
gas = 9 liters/minute, nebulizer = 35 psig, sheath gas temperature =
350°C, sheath gas flow = 11 liters/minute, capillary voltage = 3,500
V, and nozzle voltage = 1,000 V. Spectra were collected at a rate
of 1/second, corresponding to 8,133 transients/spectrum. The raw
data were converted to mzXML files using the msconvert tool in the
ProteoWizard software suite (81) and uploaded to XCMS Online
(82) to generate the features table listing all detected ions and their
aligned retention times (https://xcmsonline.scripps.edu; Public
Shares Job ID 1027173) (83). The parameters used in XCMS Online
are listed in Supplemental Table 4; P values and fold-change cutoffs of 0.01 and 20, respectively, were applied.
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The features table was then processed in R to search for features
whose m/z matched to species in the fatty acid elongation pathway
as detailed in KEGG (38, 39). Consideration was given for enrichment of 13C labels in each species by grouping features with similar
retention times (<0.2-minute range) and whose m/z values were offset from the mass of an unlabeled acyl-CoA species by whole-number multiples of the mass difference between 12C and 13C (1.00335
amu). Where multiple groups of such features, known as isotopologs, matched to a single acyl-CoA species, a selection of the single group to which the species was assigned was made based on the
following criteria: (a) minimum of 3 isotopologs represented in the
group; (b) statistically significant difference (P < 0.05, by Student’s
t test) in abundance between control and HMGCS2-deficient samples for at least 1 isotopolog in the group; and (c) proximity of the
group’s retention time to that of other groups assigned to acyl-CoAs,
given that these species are all chemically similar and are expected
to elute close to one another. Where a single group matched to multiple potential acyl-CoA species, all possible identities are listed
in Supplemental Table 5, but for the plot in Figure 5D, the 978 m/z
group was assigned to tetredecanoyl-CoA due to the lower number
of 13C labels that would be incorporated into that molecule. The
identity of acetyl-CoA was verified by using an acetyl-CoA standard
(Sigma-Aldrich) dissolved in 1:1 ACN/water, with observation of
808.1140 and 808.1127 m/z unique peaks at retention times of 37.9
and 40.0 minutes, respectively. The summed intensities of these
peaks and their associated isotopolog groups were then determined
in liver extracts of control and HMGCS2 ASO–treated animals.
To quantify differential 13C-labeling of identified features, the
mzXML files described above were processed in R using XCMS (84)
and X13CMS (40), with the latter being modified to detect differences
in 13C enrichment patterns of metabolites extracted from [3-13C]pyruvate/lactate-labeled control versus HMGCS2-deficient livers (in contrast to the usual usage, in which differences are detected between
unlabeled and labeled samples of the same biological type). Enrichment patterns are defined as the distribution of metabolite abundance among the various isotopolog forms of a particular metabolite.
Differences in patterns were defined as changes in the shape of this
distribution between biological sample types, e.g., control versus
ketogenesis insufficient.
Mitochondrial isolation and respiration. Mitochondrial isolation
and respiration studies were conducted and assessed as described
previously (79, 85).
Statistics. Analyses were performed with GraphPad Prism 5.0
software (GraphPad Software). Unpaired 2-tailed Student’s t tests
and 2-way ANOVA, with Bonferroni’s correction to correct for multiple comparisons, were used as appropriate, as indicated within the
text and figure legends. Data are presented as the means ± SEM unless
otherwise indicated. A P value of less than 0.05 was considered significant, except for the LC/MS studies, in which a P value of less than 0.01
was considered significant.
Study approval. All experiments were conducted using protocols
approved by the Animal Studies Committee of Washington University.
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